Effects of Oral Administration of Antrodia Cinnamomea Products for Clinical Symptoms in Spinocerebellar Ataxia Patients
ALPS Biotech CO. LTD
60 participants
Sep 16, 2024
INTERVENTIONAL
Summary
This study aims to assess the effect of Antrodia cinnamomea on clinical symptoms in spinocerebellar ataxia patients. To investigate the advancements in neurodegenerative diseases.
Eligibility
Inclusion Criteria5
- Adults aged 30 to 70 years, whose native language is Chinese.
- Patients diagnosed with Spinocerebellar Ataxia.
- Subjects with a score below 30 on the Scale for the Assessment and Rating of Ataxia (SARA scale).
- Individuals who can read and write in Chinese and communicate in Chinese.
- Agree to participate in the study.
Exclusion Criteria4
- Patients with severe systemic diseases, such as heart or respiratory failure, liver or kidney failure, severe brain injury, prolonged bed rest, or incurable malignancies.
- Pregnant women and breastfeeding mothers.
- Patients who have taken Antrodia cinnamomea products within the last 6 months prior to the trial.
- Patients with other factors that prevent them from continuing to participate in this study.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Placebo-controlled crossover design: * Dietary Supplement: Antrodia Cinnamomea Products * Dietary Supplement: Placebo
A arm : Stage I : • Dietary Supplement: Antrodia Cinnamomea Products Stage II: • Dietary Supplement: Placebo B arm : Stage I : • Dietary Supplement: Placebo Stage II: • Dietary Supplement: Antrodia Cinnamomea Products
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06633003